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Aims Protein kinase C epsilon (PKC1) is critical for cardiac protection from ischaemia and reperfusion (IR) injury. PKC1
substrates that mediate cytoprotection reside in the mitochondria. However, the mechanism enabling mitochondrial
translocation and import of PKC1 to enable phosphorylation of these substrates is not known. Heat shock protein 90
(HSP90) is a cytoprotective protein chaperone that participates in mitochondrial import of a number of proteins.
Here, we investigated the role of HSP90 in mitochondrial import of PKC1.
Methods
and results
Using an ex vivo perfused rat heart model of IR, we found that PKC1 translocates from the cytosol to the mitochon-
drial fraction following IR. Immunogold electron microscopy and mitochondrial fractionation demonstrated that fol-
lowing IR, mitochondrial PKC1 is localized within the mitochondria, on the inner mitochondrial membrane.
Pharmacological inhibition of HSP90 prevented IR-induced interaction between PKC1 and the translocase of the
outer membrane (Tom20), reduced mitochondrial import of PKC1, and increased necrotic cell death by  70%.
Using a rational approach, we designed a 7-amino acid peptide activator of PKC1, derived from an HSP90 homolo-
gous sequence located in the C2 domain of PKC1 (termed c1HSP90). Treatment with this peptide (conjugated to
the cell permeating TAT protein-derived peptide, TAT47–57) increased PKC1–HSP90 protein–protein interaction,
enhanced mitochondrial translocation of PKC1, increased phosphorylation and activity of an intra-mitochondrial
PKC1 substrate, aldehyde dehydrogenase 2, and reduced cardiac injury in ex vivo and in vivo models of myocardial
infarction.
Conclusion Our results suggest that HSP90-mediated mitochondrial import of PKC1 plays an important role in the protection of
the myocardium from IR injury.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Protein kinase C epsilon (PKC1) activation is required and sufﬁcient
to protect the heart from ischaemia and reperfusion (IR) injury.
1–3
We recently identiﬁed mitochondrial aldehyde dehydrogenase 2
(ALDH2) as an intra-mitochondrial substrate of PKC1,
4,5 whose phos-
phorylation and activation by PKC1 is required to confer
cardioprotection.
4 Additional mitochondrial substrates of PKC1
include cytochrome c oxidase subunit IV (COIV),
6 a PKC1 substrate
in cardiac myocytes,
6 neuronal cells,
7 and the lens.
8 PKC1 activation
also prevents opening of the mitochondrial permeability transition
pore (MPTP)
9 and can promote mitochondrial ATP-sensitive
K
+ channel (mitoKATP) opening at the inner mitochondrial
membrane (IMM),
10 although whether this reﬂects PKC1-mediated
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doi:10.1093/cvr/cvq154phosphorylation of mitoKATP awaits identiﬁcation of the native
channel protein.
A hallmark of PKC activation is translocation of the active enzyme
from the cytosol to the cell particulate fraction and a variety of
cytoprotective stimuli that activate PKC1, including ischaemic precon-
ditioning,
11 ethanol,
4,5 urocortin,
12 or transgenic expression of consti-
tutively active PKC1,
13 result in elevated mitochondrial levels of
PKC1. However, not all studies support a role for mitochondrial
PKC1 in cardioprotection.
14,15 Further, although PKC1 substrates
have been shown to reside within mitochondria, the mechanism
enabling mitochondrial import of PKC1 has not yet been described.
Mitochondrial proteins encoded by nuclear DNA are imported into
the mitochondria in a co-translational process,
16 using a 20–
50-amino acid residue mitochondrial targeting signal that is recognized
by the mitochondrial import receptor, Tom20. PKC1 does not
contain a mitochondrial targeting sequence. However, proteins that
lack this sequence can be imported into mitochondria in a process
mediated by the stress chaperone protein, heat shock protein 90
(HSP90).
17,18 Here, we examined the role of HSP90 in mediating
mitochondrial translocation of PKC1 and its effect on cardiac ischae-
mia/reperfusion.
2. Methods
2.1 Ex vivo model of cardiac
ischaemia–reperfusion
The investigation conforms with the Guide for the Care and Use of Lab-
oratory Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996). All protocols were approved by
the Stanford University Institutional Animal Care and Use Committee.
Hearts from male Wistar rats (275–300 g) were perfused via the aorta
at 10 mL/min with oxygenated Krebs–Henseleit buffer at 378C. Hearts
were subjected to 35 min global, no-ﬂow ischaemia followed by 15 min
reperfusion. HSP90 inhibitors, geldanamycin (GA; 1 mM) or radicicol
(RAD; 1 mM), were perfused during the entire reperfusion period
(Figure 1A). Cardiac damage was assessed by creatine phosphokinase
(CPK) release into the perfusate (Equal Diagnostics, CT, USA). The
c1HSP90 peptide (1 mM) was perfused for 10 min prior to ischaemia
and during the reperfusion period, in the absence and presence of GA
(1 mM; Figure 5A).
2.2 Subcellular fractionation
Heart ventricles were homogenized in ice cold mannitol–sucrose (MS)
buffer using a Polytron homogenizer. The heart homogenate was ﬁltered
through gauze then centrifuged at 700 g × 5 min. The resultant super-
natant was ﬁltered then centrifuged at 10 000 g × 10 min to pellet mito-
chondria. Mitochondrial pellets were washed three times and
resuspended in 200 mL MS buffer. Mitoplasts were generated as
described.
19,20 Mitochondria (50 mLo f1 0mg/mL) were resuspended in
450 mL hypotonic buffer (5 mM Tris–HCl and 1 mM EDTA, pH 7.4)
and incubated on ice for 15 min before centrifugation at 20 000 g for
10 min at 48C. Mitoplasts were then resuspended in 450 mL hypotonic
buffer and sonicated on ice to disrupt the IMM. The solution was then
spun at 100 000 g for 40 min with the resultant pellet containing the
IMM-enriched fraction and the supernatant containing the matrix-
enriched fraction. Submitochondrial particles (SMPs) were generated as
described.
19,21 Mitochondria (10 mg/mL in MS buffer) were sonicated
3 × 2 min on ice with 1 min intervals. The solution was spun at
10 000 g for 10 min to pellet unbroken mitochondria and the resultant
supernatant spun at 100 000 g for 30 min to pellet SMPs.
2.3 Western blotting
Ten micrograms of protein were separated by SDS–PAGE and then trans-
ferred to nitrocellulose. Membranes were blocked with 5% milk in Tris-
buffered saline (pH 7.5) containing 0.05% Tween (TBS-T), incubated
with primary antibody overnight, washed three times in TBS-T, and
then incubated with IgG secondary antibody linked to horseradish peroxi-
dase. Protein bands were visualized using chemiluminescence and quanti-
ﬁed using ImageJ (NIH).
2.4 Immunoprecipitation
Five hundred micrograms of protein were suspended in 1 mL of immuno-
precipitation (IP) buffer and incubated with 2 mg PKC1, HSP90, Tom20, or
ALDH2 antibodies (Santa Cruz Biotechnology) for 2 h, followed by over-
night incubation with Protein A/G beads at 48C. Beads were washed three
times in IP buffer and immunoprecipitated proteins detected by western
blotting.
2.5 Immunogold electron microscopy
Isolated mitochondria were ﬁxed in 4% paraformaldehyde/0.025% gluter-
aldehyde and 80 nm sections mounted on Ni grids. Mitochondria were
incubated with blocking solution, followed by PKC1 antibody (1:100 in
blocking solution), followed by goat anti-rabbit IgG conjugated to 10 nm
gold particles (Ted Pella Inc.) (1:100 in blocking solution). Mitochondria
were imaged using a JEOL 1230 electron microscope. Incubation with sec-
ondary antibody (IgG) alone served as controls.
2.6 In vitro mitochondrial translocation assay
Isolated mitochondria were incubated with recombinant PKC1 with or
without diacylglycerol and phosphatidylserine (DAG/PS; 1 mM; PKC acti-
vators), hydrogen peroxide (H2O2; 50 mM), or rabbit reticulocyte lysate
(RRL; source of HSP90), and with or without 1 mM c1HSP90. Mitochon-
drial translocation of recombinant PKC1 was assessed by western
blotting.
2.7 Sequence alignments
Sequences of the human PKC family members were aligned using
ClustalW. Human PKC1 (accession no.: NP_005391.1) was aligned with
human HSP90a (accession no.: NP_005339) and HSP90b (accession
no.: NP_031381) using L-ALIGN, using the Blosum 80 scoring matrix.
2.8 In vivo model of cardiac ischaemia–
reperfusion
Male Wistar rats (275–300 g) were anaesthetized with isoﬂurane and
myocardial ischaemia was induced by ligation of the left anterior descend-
ing (LAD) coronary artery for 35 min, followed by 24 h of reperfusion.
Control TAT or c1HSP90 peptides (1 mg/kg in 400 mL saline) were
injected intraperitoneally 15 min prior to LAD ligation and 5 min before
reperfusion onset. Fractional shortening was determined by echocardio-
graphy. Area at risk (AAR) was assessed by re-occlusion of the LAD at
the previous suture site, followed by intravenous injection of Evans Blue
(1.0 mg/kg). The heart was sectioned into transverse slices, which were
incubated with 1% trimethyl tetrazolium chloride (TTC), weighed, and
photographed by a digital camera. AAR (negative for Evans Blue) and
infarct area (negative for TTC) were quantiﬁed using ImageJ and infarct
size was calculated as (infarct area/AAR of infarction) × 100 (%).
2.9 Statistical analysis
All data are expressed as mean+SEM. Statistical analyses between two
groups was performed using the unpaired Student’s t-test. Statistical analy-
sis of more than two groups was performed using one-way ANOVA with
Dunnett’s multiple comparisons post hoc test. A P-value of ,0.05 was
considered statistically signiﬁcant.
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3.1 HSP90 activity is required for
IR-induced mitochondrial translocation
of PKC1
Thirty-ﬁve-minute global ischaemia followed by 15 min reperfusion
induced translocation of PKC1 and PKCd to the mitochondrial fraction
(Figure1A,B,andD;n ¼ 5;P , 0.05).HSP90inhibitionwithGA(1 mM),
during reperfusion (Figure 1A), attenuated IR-induced mitochondrial
translocation of PKC1 by 54% (Figure 1B and C, left panel, n ¼ 5; P ,
0.01), but not mitochondrial translocation of PKCd (Figure 1B and C,
right panel, n ¼ 5). GA had no effect on total PKC1 levels (Figure 1B),
indicating that reduced mitochondrial PKC1 translocation was not
due to increased PKC1 degradation. HSP90 inhibition with RAD
(1 mM), which is structurally unrelated to GA,
22 also blocked
IR-inducedmitochondrialtranslocationofPKC1(Figure1D).Mitochon-
drial purity was conﬁrmed by electron microscopy and western blot
analysiswithproteinmarkersofcytosolic(GAPDH),plasmamembrane
(b-integrin),and mitochondrial fractions (mitofusion-1)(Figure1E). GA
treatment during reperfusion also increased CPK release by  70%
when compared with IR alone (Figure 1F; P , 0.05; n ¼ 7), but caused
no damage in normoxic perfused hearts, even when used at ﬁve-fold
higher concentration (Figure 1F).
Figure 1 Inhibition of HSP90 reduces IR-induced PKC1 translocation to cardiac mitochondria. (A) Perfused heart protocols. (B) Western blot analy-
sis of mitochondrial PKC1 and PKCd in hearts exposed to normoxia or IR (in the absence and presence of 1 mM GA). Also shown are cytosolic
(middle panels) and total PKC1 levels (lower panels). (C) Quantiﬁcation of mitochondrial PKC1 and PKCd levels, normalized to adenine nucleotide
translocase (ANT); mean+SEM (n ¼ 5, *P , 0.05). (D) IR-induced mitochondrial translocation of PKC1 in the presence of another HSP90 inhibitor,
RAD (1 mM). (E) Purity of the mitochondrial preparation conﬁrmed by electron microscopy (scale bar ¼ 1 mm) and western blotting for marker
proteins of the cytosol (GAPDH), the mitochondria (MTF-1), or the plasma membrane (b-integrin). (F) GA effect on CPK release under normoxic
and IR conditions; mean+SEM (n ¼ 5–7, *P , 0.05).
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proceeds via the HSP90–Tom20 import
system
Under normoxic conditions, there was no physical association
between PKC1 and HSP90 or between PKC1 and Tom20 at the mito-
chondria (Figure 2A). However, PKC1 co-immunoprecipitated with
both HSP90 and Tom20 in mitochondria after IR. IR-induced co-IP
was observed when immunoblotting the PKC1 immunoprecipitate
for the presence of HSP90 or Tom20, and conﬁrmed by the presence
of PKC1 in the HSP90 or Tom20 immunoprecipitate. Importantly,
IR-induced physical association between PKC1–HSP90 and PKC1–
Tom20 was inhibited by GA, suggesting that HSP90 activity was
required. No association between PKC1 and HSP90 was found in
the cytosol under any conditions (Figure 2B), suggesting that
IR-induced PKC1–HSP90 interaction occurs following mitochondrial
translocation of PKC1.
3.3 Mitochondrial PKC1 is bound
to the IMM
Mitochondrial PKC1 location was examined by immunogold elec-
tron microscopy (EM) and mitochondrial subfractionation
(Figure 3). Gold particles (representing bound PKC1 antibody)
were found predominantly at the IMM (Figure 3A, right upper
panel). Mitochondrial PKC1 levels increased by 2.3-fold when com-
pared with normoxic conditions (Figure 3A, IR vs. normoxia, and
Figure 3B, n ¼ 3; analysing 60 mitochondria/per group, P , 0.05).
The IR-induced increase in PKC1 levels was attenuated by GA
(Figure 3A,I R + GA and Figure 3B, n ¼ 3, P , 0.05). There was a
complete absence of staining when mitochondria were incubated
with anti-rabbit IgG conjugated to immunogold, without prior incu-
bation with the PKC1 antibody (IgG control), excluding non-speciﬁc
binding due to IgG.
To further investigate the localization of PKC1 in the mitochondria,
SMPs were prepared from hearts subjected to IR. SMPs were gener-
ated by sonication, creating inside-out mitochondrial vesicles, expos-
ing IMM-associated proteins that face the matrix, and sequestering
proteins that face the inner mitochondrial space, like cytochrome c,
within the inverted mitochondrial vesicle
21 (Figure 3C). Exposure to
a 200 mM Na2CO3 carbonate wash at pH 11.5 (which removes
strongly bound, but non-integral, membrane proteins) removed
PKC1 from the IMM, whereas exposure to 400 mM KCl high-salt
wash (which removes loosely associated proteins from membranes)
did not dislodge PKC1 from this fraction (Figure 3D, upper left
panel). Trypsin, which cannot cross membranes, completely
removed PKC1 from these inside-out mitochondrial vesicles
(Figure 3D, top right panel). That trypsin could access PKC1 suggests
that PKC1 is present on the exposed (matrix) side of the IMM in the
SMP preparation.
21 In contrast, the levels of cytochrome c, present in
the space between the inner and the outer mitochondrial membranes
(and therefore resides inside the SMP vesicles), were unaffected by
trypsin digestion (Figure 3D, lower right panel), whereas the adenine
nucleotide translocase (ANT), an integral IMM protein, showed a
similar sensitivity to trypsin digestion as PKC1 (Figure 3D, middle
right panel).
Mitochondria from hearts exposed to normoxia or IR were also
subfractionated to yield IMM- and matrix-enriched components
(Figure 3C, right scheme, and Figure 3E), which were then probed
for PKC1 (Figure 3E, upper panels). [Purity was conﬁrmed using anti-
bodies against ANT (a marker of IMM), Grp75 (a mitochondrial
matrix marker), and enolase (a cytosolic marker).] Similar to the
Figure 2 IR-induced co-IP of mitochondrial PKC1 with HSP90 or Tom20 requires HSP90 chaperone activity. Co-IP of mitochondrial (A) and cyto-
solic (B) fractions from hearts exposed to normoxia or IR with and without GA (1 mM); representative of ﬁve experiments. The presence of HSP90 or
Tom20 in the PKC1 immunoprecipitate (top) was conﬁrmed by the presence of PKC1 in the HSP90 (middle) or Tom20 (bottom) immunoprecipi-
tates. None of the proteins could immunoprecipitate with IgG beads alone. Input (mitochondrial lysate) controls are also provided.
G.R. Budas et al. 86EM analysis, PKC1 in the IMM-enriched fraction increased following
exposure to IR and was reduced by GA.
3.4 A rationally designed peptide activator
of HSP90 and PKC1 interaction (c1HSP90)
increases PKC1 translocation to cardiac
mitochondria
We previously identiﬁed peptide activators of PKC1 that induce
protein–protein interaction between PKC1 and its anchoring
protein, 1RACK.
3 Speciﬁcally, an 8-amino acid peptide corresponding
to a sequence in the C2 domain of PKC1 that is homologous to a
sequence in 1RACK
3 (hence termed pseudo-1RACK or c1RACK
peptide) was found to be an allosteric agonist of PKC1. c1RACK
interferes with the auto-inhibitory intra-molecular interaction within
PKC1, stabilizing PKC1 in a conformational state in which the 1RACK-
binding site on PKC1 is available for inter-molecular interaction with
1RACK.
3,23 The observation that PKC1 only binds HSP90 upon acti-
vation (Figure 2), as is the case with PKC1-1RACK binding, led us to
reason that the HSP90-binding site on PKC1 may also participate in
an auto-inhibitory intra-molecular interaction when PKC1 is inactive.
Using L-ALIGN sequence alignment software, we identiﬁed
Figure 3 PKC1 associates with the IMM. (A) Electron micrographs of PKC1 immunogold labelling in cardiac mitochondria. Localization on the IMM
is indicated by arrows (scale bar ¼ 0.5 mm). Also included is an IgG control example. (B) Quantitation of mitochondrial PKC1 immunogold staining;
mean +SEM (n ¼ 3 animals, *P , 0.05). (C) Schematic of protocols used to fractionate mitochondria (SMPs). (D) SMPs from IR hearts were exposed
to 200 mM Na2CO3 (pH 11.5), 400 mM KCl (salt), or trypsin digestion and levels of PKC1, the IMM protein, ANT, and the IMS protein, cytochrome c,
were determined by western blotting. (E) IMM and mitochondrial matrix-enriched and cytosolic fractions were probed for PKC1, ANT (a marker of
IMM), glucose response protein (Grp75; a marker of matrix fraction), and enolase (a cytosolic marker) from hearts subjected to normoxia, IR, or IR in
the presence of 1 mM GA.
HSP90-mediated mitochondrial import of PKC1 87PKDNEER at the end of the C2 domain of PKC1 (amino acids 139–
145; Figure 4A) to be homologous to PEDEEEK, found at the end of
the middle domain of HSP90 (amino acids 552–558 on HSP90a
and 544–550 on HSP90b; Figure 4A). There are two charge differ-
ences between these homologous sequences (Lys
140 and Asn
142 on
PKC1 compared with Glu
553 and Glu
555 on HSP90a; red and under-
lined in Figure 4A). Such charge differences between the sequences
were found in each of the other previous pseudo-site-derived pep-
tides.
24,25 Further, the HSP90 homologous sequence on PKC1 is
not found in any other members of the PKC family (Figure 4C), but
is evolutionary conserved in PKC1 in a variety of species, including
human, rat, mouse, and Xenopus. We synthesized a peptide corre-
sponding to the HSP90 homology region in PKC1 (termed
c1HSP90) and conjugated it, via cysteine–cysteine bond, to the cell
permeating TAT protein-derived peptide, TAT47–57
25 (Figure 4B).
The effect of c1HSP90 on mitochondrial PKC1 translocation was
initially determined, in vitro. Isolated cardiac mitochondria were
incubated with recombinant PKC1 in the absence or presence of
the PKC activators, DAG/PS (1mM), and/or with hydrogen peroxide
(H2O2; 50 mM Figure 4D and E). Unstimulated recombinant PKC1 did
not associate with the mitochondria. However, on activation with
DAG/PS, there was substantial mitochondrial PKC1 association
(Figure 4D). H2O2 induced only a limited PKC1 translocation and
did not increase the mitochondrial PKC1 translocation induced by
DAG/PS (Figure 4D). RRL, used as an exogenous source of
HSP90,
26 did not increase PKC1 association with the mitochondria,
suggesting that HSP90 is already present at the mitochondria. This
was also demonstrated by the data in Figure 2A (see also Figure 5D),
in which HSP90 was detected at the mitochondria under normoxic
conditions, and in agreement with previous data.
27 In the presence
of c1HSP90 peptide (1 mM, Figure 4E), the H2O2-induced mitochon-
drial association of PKC1 was enhanced (Figure 4E, second to last
lane), suggesting that c1HSP90 enhances oxidative stress-induced
mitochondrial translocation of PKC1.
Figure 4 A rationally designed peptide activator of HSP90 and PKC1 interaction (c1HSP90) increases mitochondrial PKC1 translocation. (A) Hom-
ologous sequence between PKC1 and HSP90 displaying charge differences (Lys
140 and Asn
142 in human PKC1 and Glu
553 and Glu
555 in human
HSP90a). Also shown is a scheme indicating the location of the homologous sequences (red) on PKC1 and HSP90. (B) c1HSP90 peptide conjugated
to cell penetrating TAT47–57 peptide. (C) Alignment of human PKC isozymes, indicating that the c1HSP90 sequence is unique for the PKC1 isozyme.
Identical and homologous sequences are indicated by asterisks and ﬁlled circles, respectively. Mitochondrial association of recombinant PKC1 after
activation with DAG/PS (1 mM) and/or H2O2 (50 mM) and with RRL in the absence (D) and presence (E)o f1mM c1HSP90. VDAC is used as a
loading control.
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PKC1 translocation, activates
mitochondrial ALDH2, and reduces
IR injury
We determined whether c1HSP90 peptide increased mitochondrial
translocation of PKC1 in ex vivo hearts. Mitochondria isolated from
hearts subjected to IR in the presence of 1 mM c1HSP90 (see proto-
cols in Figure 5A) had a 35+7% increase in PKC1 (n ¼ 5, P , 0.05;
Figure 5B and C), when compared with the IR alone group. Mitochon-
drial PKCd translocation was unaffected by c1HSP90 treatment
(Figure 5B and C), indicating speciﬁcity for PKC1. Further, c1HSP90
did not affect PKC1 translocation to the plasma membrane
(Figure 5B, lower panels), indicating a selective increase in mitochon-
drial PKC1. There was no effect of the TAT carrier peptide alone
on mitochondrial translocation of PKC1 or CK release (see Sup-
plementary material online, Figure S1). Treatment with c1HSP90
also enhanced IR-induced physical interaction between HSP90 and
Figure 5 c1HSP90 enhances mitochondrial PKC1 translocation, increases ALDH2 activity, and reduces cardiac damage by ischaemia/reperfusion,
ex vivo.( A) IR protocols in the presence or absence of c1HSP90 peptide (1 mM) and GA (1 mM). (B) c1HSP90 peptide increased IR-induced mito-
chondrial translocation of PKC1 but was without effect on mitochondrial translocation of PKCd.( C) Quantiﬁcation of data in (B); mean+S.E.M
(n ¼ 7, *P , 0.05). (D) Co-IP of mitochondrial HSP90 and PKC1 in normoxic and IR hearts in the absence and presence of c1HSP90 peptide or
GA. (E) Mitochondrial ALDH2 activity in hearts exposed to IR in the absence and presence of c1HSP90 and GA. (F) Shift of immunoreactive
ALDH2 on 2D IEF gels towards acidic pI by c1HSP90 when compared with IR alone, suggesting increased ALDH2 phosphorylation. (G) ALDH2
phosphorylation detected by immunoblotting the ALDH2 immunoprecipitate with anti-phospho Ser/Thr antibody (upper band on blot, distinct
from IgG). PKC1 co-IP was also assessed by immunoblotting the ALDH2 immunoprecipitate (middle lane). (H) CPK release following IR injury, in
hearts treated with and without c1HSP90 and GA; mean+SEM (n ¼ 6, *P , 0.05).
HSP90-mediated mitochondrial import of PKC1 89PKC1 and the c1HSP90-induced increase in PKC1–HSP90 associ-
ation was substantially reduced by pharmacological inhibition of
HSP90 with GA (Figure 5D).
We previously found that selective PKC1 activation results in
ALDH2 phosphorylation and increases ALDH2 activity,
4 and that
ALDH2 activity correlates with cardioprotection from IR [R
2 ¼
0.97].
4 When compared with control-treated hearts, c1HSP90 treat-
ment caused a 38+9% increase in ALDH2 activity (Figure 5E; n ¼ 6,
P , 0.05), an effect that was blocked by HSP90 inhibition with GA
(Figure 5E; n ¼ 6, P , 0.05). To determine whether increased
ALDH2 activity was due to increased ALDH2 phosphorylation, we
performed two-dimensional gel immunoelectrophoresis (2D IEF) fol-
lowed by immunoblotting with anti-ALDH2 antibodies. Similar to our
study using c1RACK,
4 immunoreactive ALDH2 shifted to more acidic
pI ranges after c1HSP90 treatment when compared with IR alone
(Figure 5F), suggesting increased ALDH2 phosphorylation. This was
also conﬁrmed directly by immunoblotting the ALDH2 immunopreci-
pitate with anti-phospho Ser/Thr antibody (Figure 5G). The
c1HSP90-induced increase in ALDH2 phosphorylation and activity
was prevented by GA, demonstrating the requirement of HSP90. In
addition, c1HSP90 treatment increased ALDH2-PKC1 co-IP in
these samples (Figure 5G, lane 3). Finally, we determined the effect
of c1HSP90 peptide on cardiac damage following IR. Hearts treated
with c1HSP90 peptide had  50% reduced IR-induced cardiac
damage as assessed by CPK release (Figure 5H; P , 0.05, n ¼ 6),
which was attenuated by HSP90 inhibition (Figure 5H; P , 0.05, n ¼
5).
3.6 c1HSP90 peptide reduces infarct size
and increases functional recovery following
ischaemia and reperfusion injury, in vivo
We used an in vivo model of acute myocardial infarction in adult male
rats that consisted of 35 min ischaemia followed by 24 h reperfusion.
Rats were injected intraperitoneally with either c1HSP90 or with the
control carrier peptide, TAT, (1 mg/kg in 400 mL saline, each), which
were administered 15 min before LAD occlusion and 5 min before
the onset of reperfusion (Figure 6A). [The dose and route of adminis-
tration were chosen based on our previous work using other TAT-
conjugated peptides, such as c1RACK and 1V1–2
28,29.] Treatment with
c1HSP90 reduced infarct size by  30% relative to control animals
(Figure 6B; n ¼ 6, P , 0.05), which had equivalent AAR for infarction
(Figure 6C). Treatment with c1HSP90 also led to improvement in
cardiac function; fractional shortening increased from 31+2% in
TAT control-treated rats to 40+3% in rats treated with c1HSP90
(Figure 6D; n ¼ 6, P , 0.05).
4. Discussion
PKC1 is critical for cardioprotection from IR injury. A number of
studies have demonstrated that PKC1-mediated protection is due
to phosphorylation of mitochondrial proteins.
4,6,8,13,30 Here, we
report that mitochondrial import of PKC1 is mediated by HSP90
and plays a crucial cardioprotective role. Although previous studies
have demonstrated PKC1 activity within mitochondria,
6–8,10,30 to
our knowledge, this study is the ﬁrst description of interaction
between PKC1 and the mitochondrial import machinery and suggests
a possible mechanism for mitochondrial translocation of PKC1.
We also describe a peptide, designed based on PKC1–HSP90
protein–protein interaction sites (c1HSP90), which increases mito-
chondrial PKC1-HSP90 interaction, promotes mitochondrial translo-
cation of PKC1, and reduces infarct size ex vivo and in vivo.
A number of cardioprotective stimuli have been found to enhance
mitochondrial translocation of PKC,
4,5,9,11,12,30 whereas other studies
did not support a role for mitochondrial PKC1 in cardioprotec-
tion.
14,15 This discrepancy may be explained by differences in stimu-
lation or models used, the time point at which the translocation
analyses were performed, or differences in cellular fractionation tech-
niques. Here, we found that IR-induced mitochondrial translocation of
both PKC1 and PKCd when analysed 15 min after reperfusion began.
HSP90 inhibition during reperfusion attenuated mitochondrial translo-
cation of PKC1, but not that of PKCd (Figure 1). Electron microscopy
and mitochondrial subfractionation analyses conﬁrmed that
intra-mitochondrial PKC1 levels are increased by IR in an HSP90-
dependent manner and demonstrated that mitochondrial PKC1 is
localized at the matrix side of the IMM (Figure 3). These data are con-
sistent with recent studies reporting PKC1 at the IMM,
10,30 and with
data demonstrating that PKC1 phosphorylates a number of intra-
mitochondrial proteins.
4–6,8,13,30 Because mitochondrial translocation
of PKC1 occurs rapidly, with a corresponding decline in cytosolic
PKC1 levels, and since the total cellular PKC1 levels do not change
(Figure 1B), our data suggest that HSP90 enables dynamic mitochon-
drial translocation of PKC1 in response to IR. HSP90-mediated mito-
chondrial import of proteins proceeds via the translocase of the outer
membrane (TOM) multiprotein complex through recognition of the
chaperoned protein by the import receptors, Tom20, Tom22, or
Tom70.
16 We found that IR induced physical association between
PKC1 and mitochondrial Tom20, which was prevented by GA.
These data suggest that stimulus-induced mitochondrial import of
PKC1 proceeds via an HSP90-dependent interaction with the TOM
import complex. HSP90 inhibition did not affect IR-induced mitochon-
drial translocation of PKCd. Other chaperones including HSP70,
HSC70, and HSP40 mediate mitochondrial import of proteins;
17,31
therefore, it is possible that an another chaperone mediates mito-
chondrial import of PKCd.
HSP90 inhibition with GA during reperfusion resulted in a 70%
increase in CK release, indicating that HSP90 mediates a cytoprotec-
tive function during reperfusion of ischaemic myocardium. However,
HSP90 mediates a number of functions, including mitochondrial trans-
location of other cytoprotective proteins;
18 therefore, increased
damage due to GA was not exclusively due to effects on mitochon-
drial PKC1. We therefore sought a means to selectively modulate
PKC1–HSP90 interaction. Because PKC1 is regulated by multiple
intra-molecular interactions,
23,32 we reasoned that an inhibitory intra-
molecular interaction may exist between the HSP90-binding site in
PKC1 and a sequence within PKC1 that shares homology with a
region on HSP90 (Figure 6E). The c1HSP90 peptide corresponds to
such a 7-amino acid sequence homology between the C2 domain
of PKC1, which is homologous with a sequence in the middle
domain of HSP90. The C2 domain of PKC1 is known to mediate
PKC1 protein–protein interactions,
33 and the corresponding
sequence on HSP90 resides within a region that is essential for
HSP90 protein–protein interaction.
34 Importantly, charge differences
exist between these homologous sequences, characteristic of inter-
action sites within PKC.
25,33
Our data demonstrate that c1HSP90 treatment enhanced
IR-induced protein–protein interaction between PKC1 and HSP90
(Figure 5D), enhanced mitochondrial PKC1 translocation (Figures 4D
G.R. Budas et al. 90and E, and 5B–D), and decreased cardiac injury (Figures 5H and 6B).
The c1HSP90-induced effects were attenuated by GA, demonstrating
that c1HSP90 requires HSP90 (Figure 5E–H). The c1HSP90 peptide
did not affect PKCd mitochondrial translocation, demonstrating selec-
tivity for PKC1. Since PKC1 does not associate with HSP90 until acti-
vation with IR, it is likely that PKC1–HSP90 interaction is dependent
on a conformational change that occurs upon PKC1 activation, which
exposes the HSP90-binding site. We propose that c1HSP90 stabilizes
the activated PKC1 in a transient conformation that promotes its
binding to HSP90, resulting in enhanced mitochondrial import of
PKC1 (Figure 6E).
We recently identiﬁed mitochondrial ALDH2 as a PKC1 substrate,
whose activity correlates with cardioprotection from IR.
4 Here, we
showed that c1HSP90 increased phosphorylation and activity of
ALDH2. Although the current study focused on ALDH2, PKC1 can
regulate other mitochondrial functions that mediate cytoprotection,
including regulation of mitochondrial respiration and ROS production
(mediated by phosphorylation of COIV by PKC1),
6,7,30 regulation of
mitochondrial K
+ ﬂux and mitochondrial matrix swelling,
10 and inhi-
bition of MPTP opening.
9
In summary, our results demonstrate that mitochondrial import of
PKC1 is mediated by HSP90 and is required for cardiac protection
against IR. Our data suggest a possible mechanism by which PKC1
can access cytoprotective substrates located within the mitochondria
to confer cardioprotection. We also describe a novel peptide activa-
tor of PKC1, c1HSP90, which promotes mitochondrial PKC1–HSP90
interaction and may have therapeutic use in the treatment of cardiac
IR injury.
Figure 6 c1HSP90 reduces infarct size and improves functional recovery following ischaemia/reperfusion injury in vivo.( A)A nin vivo model of myo-
cardial infarction (B) c1HSP90 reduced infarct size from 57+5% in control (TAT carrier treated) to 41+6% (n ¼ 6, *P , 0.05). (C) AAR was equal
in both experimental groups. (D) c1HSP90 improved fractional shortening from 31+2% in controls, to 40+3% (n ¼ 6, *P , 0.05). Histograms
show mean+SEM (n ¼ 6, *P , 0.05). (E) A proposed scheme of mitochondrial PKC1 translocation. On activation, PKC1 undergoes a conformational
change, exposing the HSP90-binding site, enabling HSP90–PKC1 interaction at the mitochondria and PKC1 interaction with TOM, promoting mito-
chondrial import of PKC1. The c1HSP90 peptide binds to the open form of PKC1, stabilizing the enzyme in a conformation that promotes PKC1–
HSP90 interaction. Because the afﬁnity of PKC1 for the c1HSP90 peptide is lower than that of the native PKC1-binding site on HSP90, the peptide is
displaced when PKC1 binds HSP90 at the mitochondria.
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